{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:12:47Z","timestamp":1794017567568,"version":"4.8.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.vaccine.2018.11.056","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T10:43:09Z","timestamp":1543920189000},"page":"226-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"title":["Cost-effectiveness of adult vaccinations: A systematic review"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8869-5561","authenticated-orcid":false,"given":"Andrew J.","family":"Leidner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6695-3141","authenticated-orcid":false,"given":"Harrell W.","family":"Chesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Biggerstaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-9312","authenticated-orcid":false,"given":"Charles","family":"Stoecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7121-7635","authenticated-orcid":false,"given":"Aaron M.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Dooling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn B.","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2018.11.056_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7326\/M16-2936","article-title":"Recommended immunization schedule for adults aged 19 years or older, United States, 2017* recommended immunization schedule for adults, United States, 2017","volume":"166","author":"Kim","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2018.11.056_b0010","doi-asserted-by":"crossref","first-page":"D114","DOI":"10.1016\/j.vaccine.2015.09.054","article-title":"Meeting the challenges of immunizing adults","volume":"33","author":"Bridges","year":"2015","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2018.11.056_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6611a1","article-title":"Surveillance of vaccination coverage among adult populations\u2014United States, 2015. Morbidity and mortality weekly report","volume":"66","author":"Williams","year":"2017","journal-title":"Surveillance Summaries"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.056_b0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10935-015-0394-3","article-title":"Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013","volume":"36","author":"McLaughlin","year":"2015","journal-title":"J Primary Prevent"},{"issue":"52","key":"10.1016\/j.vaccine.2018.11.056_b0025","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1016\/j.vaccine.2017.11.001","article-title":"Attitudes about adult vaccines and reminder\/recall in a safety net population","volume":"35","author":"Albright","year":"2017","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2018.11.056_b0030","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1080\/21645515.2017.1371380","article-title":"Immunization attitudes and practices among family medicine providers","volume":"13","author":"Bonville","year":"2017","journal-title":"Human Vaccines Immunotherap"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2018.11.056_b0035","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0264-410X(01)00463-7","article-title":"Adult pneumococcal vaccination: a review of physician and patient barriers","volume":"20","author":"Mieczkowski","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.056_b0040","series-title":"Making prevention the priority \u2013 how to boost adult immunization rates, in Becker's Hospital Review","author":"Zimmerman","year":"2017"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.056_b0045","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/003335491613100216","article-title":"Physician attitudes toward adult vaccines and other preventive practices, United States, 2012","volume":"131","author":"Hurley","year":"2016","journal-title":"Public Health Rep"},{"issue":"23","key":"10.1016\/j.vaccine.2018.11.056_b0050","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1016\/j.vaccine.2017.04.028","article-title":"Awareness among adults of vaccine-preventable diseases and recommended vaccinations, United States, 2015","volume":"35","author":"Lu","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.056_b0055","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.vaccine.2017.12.016","article-title":"Association of provider recommendation and offer and influenza vaccination among adults aged \u226518 years\u2013United States","volume":"36","author":"Lu","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.056_b0060","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40273-012-0020-7","article-title":"A systematic review of the cost effectiveness of herpes zoster vaccination","volume":"31","author":"Szucs","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2018.11.056_b0065","first-page":"1828-1843","article-title":"Systematic review of the cost-effectiveness of influenza immunization programs","volume":"35 (14)","author":"Ting","year":"2017","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2018.11.056_b0070","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.vaccine.2014.01.058","article-title":"Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review","volume":"32","author":"Kawai","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.056_b0075","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00019053-200927020-00004","article-title":"Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review","volume":"27","author":"Marra","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"19","key":"10.1016\/j.vaccine.2018.11.056_b0080","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1016\/j.vaccine.2005.12.043","article-title":"Vaccinating healthcare workers against influenza to protect the vulnerable\u2014is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation","volume":"24","author":"Burls","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.056_b0085","doi-asserted-by":"crossref","first-page":"156","DOI":"10.15585\/mmwr.mm6705e2","article-title":"Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger\u2014United States, 2018","volume":"67","author":"Robinson","year":"2018","journal-title":"Morb Mortal Wkly Rep"},{"issue":"33","key":"10.1016\/j.vaccine.2018.11.056_b0090","doi-asserted-by":"crossref","first-page":"874","DOI":"10.15585\/mmwr.mm6633a2","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years\u2014United States, 2016","volume":"66","author":"Walker","year":"2017","journal-title":"Morb Mortal Wkly Rep"},{"issue":"26","key":"10.1016\/j.vaccine.2018.11.056_b0095","first-page":"6","article-title":"Human papillomavirus\u2013associated cancers\u2014United States, 2008\u20132012","volume":"65","author":"Viens","year":"2016","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.11.056_b0100","series-title":"Cost-effectiveness of influenza vaccination, U.S. Congress, Editor","first-page":"1","author":"Office of Technology Assessment","year":"1981"},{"issue":"10","key":"10.1016\/j.vaccine.2018.11.056_b0105","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJM198009043031004","article-title":"Cost effectiveness of vaccination against pneumococcal pneumonia","volume":"303","author":"Willems","year":"1980","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2018.11.056_b0110","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/MAJ.0b013e318156b4bc","article-title":"Immunization for the elderly","volume":"334","author":"Bader","year":"2007","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11597310-000000000-00000","article-title":"Seasonal influenza vaccination of healthy working-age adults","volume":"72","author":"Gatwood","year":"2012","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.vaccine.2018.11.056_b0120","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.vaccine.2012.05.050","article-title":"Review of the United States universal varicella vaccination program: herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data","volume":"31","author":"Goldman","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2018.11.056_b0125","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1586\/14760584.7.6.753","article-title":"Cost-effectiveness of varicella vaccination programs: an update of the literature","volume":"7","author":"Rozenbaum","year":"2008","journal-title":"Exp Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00019053-200321010-00002","article-title":"Economic evaluations of varicella vaccination programmes","volume":"21","author":"Thiry","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.056_b0135","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2165\/11599470-000000000-00000","article-title":"The cost effectiveness of human papillomavirus vaccines","volume":"72","author":"Seto","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2018.11.056_b0140","first-page":"1","article-title":"Cost effectiveness of HPV vaccination: a systematic review of modelling approaches","author":"Pink","year":"2016","journal-title":"PharmacoEconomics"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.056_b0145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00019053-200927020-00004","article-title":"Effectiveness and cost effectiveness of human papillomavirus vaccine","volume":"27","author":"Marra","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.056_b0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00019053-200826030-00004","article-title":"Cost-effectiveness analyses of vaccination programmes","volume":"26","author":"Kim","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"10.1016\/j.vaccine.2018.11.056_b0155","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/00019053-200422110-00003","article-title":"Economic aspects of pneumococcal pneumonia","volume":"22","author":"De Graeve","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2018.11.056_b0160","first-page":"1","article-title":"Economic evaluation of vaccination programmes in older adults and the elderly: important issues and challenges","author":"Dirmesropian","year":"2016","journal-title":"PharmacoEconomics"},{"issue":"36","key":"10.1016\/j.vaccine.2018.11.056_b0165","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1016\/j.vaccine.2009.05.061","article-title":"Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions","volume":"27","author":"Ogilvie","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.056_b0170","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s11192-016-1889-2","article-title":"Factors affecting number of citations: a comprehensive review of the literature","volume":"107","author":"Tahamtan","year":"2016","journal-title":"Scientometrics"},{"key":"10.1016\/j.vaccine.2018.11.056_b0175","series-title":"Cost-effectiveness in health and medicine","author":"Neumann","year":"2016"},{"key":"10.1016\/j.vaccine.2018.11.056_b0180","series-title":"Prevention effectiveness: a guide to decision analysis and economic evaluation","author":"Haddix","year":"2003"},{"issue":"10","key":"10.1016\/j.vaccine.2018.11.056_b0185","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.11.056_b0190","unstructured":"Bureau of Labor Statistics US Dept of Labor. All items in US city average, all urban consumers, not seasonally adjusted. 2017 [cited 2017 6\/30\/2017]; Available from: http:\/\/data.bls.gov."},{"key":"10.1016\/j.vaccine.2018.11.056_b0195","unstructured":"Board of Governors of the US Federal Reserve System. Canada\/U.S. Foreign Exchange Rate [EXCAUS]. 2017 [cited 2017 6\/30\/2017]; Available from: https:\/\/fred.stlouisfed.org\/series\/EXCAUS."},{"key":"10.1016\/j.vaccine.2018.11.056_b0200","doi-asserted-by":"crossref","unstructured":"S.D. Grosse, Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold, Expert Review of Pharmacoeconomics and Outcomes Research 8 (2), 2008, 165-178.","DOI":"10.1586\/14737167.8.2.165"},{"issue":"9","key":"10.1016\/j.vaccine.2018.11.056_b0205","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2018.11.056_b0210","doi-asserted-by":"crossref","first-page":"e67260","DOI":"10.1371\/journal.pone.0067260","article-title":"Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly","volume":"8","author":"McGarry","year":"2013","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.056_b0215","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.amepre.2006.10.016","article-title":"Cost effectiveness of pertussis vaccination in adults","volume":"32","author":"Lee","year":"2007","journal-title":"Am J Prev Med"},{"issue":"6","key":"10.1016\/j.vaccine.2018.11.056_b0220","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1542\/peds.2004-2509","article-title":"Pertussis in adolescents and adults: should we vaccinate?","volume":"115","author":"Lee","year":"2005","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0225","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2337\/dc12-0759","article-title":"Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes","volume":"36","author":"Hoerger","year":"2013","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.vaccine.2018.11.056_b0230","doi-asserted-by":"crossref","first-page":"538","DOI":"10.7326\/0003-4819-151-8-200910200-00007","article-title":"Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States","volume":"151","author":"Kim","year":"2009","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.vaccine.2018.11.056_b0235","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/M15-0093","article-title":"Cost-effectiveness of herpes zoster vaccine for persons aged 50 years","volume":"163","author":"Le","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2018.11.056_b0240","doi-asserted-by":"crossref","first-page":"D83","DOI":"10.1016\/j.vaccine.2015.09.031","article-title":"Racial and ethnic disparities in vaccination coverage among adult populations in the US","volume":"33","author":"Lu","year":"2015","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2018.11.056_b0245","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ajic.2016.03.064","article-title":"Persistent racial and ethnic disparities in flu vaccination coverage: results from a population-based study","volume":"44","author":"Almario","year":"2016","journal-title":"Am J Infect Control"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.056_b0250","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/21645515.2017.1403697","article-title":"An analysis of factors associated with influenza, pneumoccocal, Tdap, and herpes zoster vaccine uptake in the US adult population and corresponding inter-state variability","volume":"14","author":"La","year":"2018","journal-title":"Human Vaccines Immunotherap"},{"issue":"36","key":"10.1016\/j.vaccine.2018.11.056_b0255","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1016\/j.vaccine.2014.06.067","article-title":"Determinants of uptake of influenza vaccination among pregnant women\u2013a systematic review","volume":"32","author":"Yuen","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.056_b0260","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M13-2332","article-title":"US physicians\u2019 perspective of adult vaccine delivery","volume":"160","author":"Hurley","year":"2014","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.056_b0265","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.amepre.2017.10.016","article-title":"Immunization practices of US obstetrician\/gynecologists for pregnant patients","volume":"54","author":"O\u2019Leary","year":"2018","journal-title":"Am J Prev Med"},{"issue":"8","key":"10.1016\/j.vaccine.2018.11.056_b0270","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.vaccine.2018.01.015","article-title":"Vaccine financing and billing in practices serving adult patients: a follow-up survey","volume":"36","author":"Lindley","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.056_b0275","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.vaccine.2013.11.050","article-title":"Vaccination benefits and cost-sharing policy for non-institutionalized adult Medicaid enrollees in the United States","volume":"32","author":"Stewart","year":"2014","journal-title":"Vaccine"},{"issue":"38","key":"10.1016\/j.vaccine.2018.11.056_b0280","first-page":"839","article-title":"Vaccination with tetanus, diphtheria, and acellular pertussis vaccine of pregnant women enrolled in Medicaid-Michigan, 2011\u20132013","volume":"63","author":"Housey","year":"2014","journal-title":"Morb Mortal Wkly Rep"},{"issue":"27","key":"10.1016\/j.vaccine.2018.11.056_b0285","first-page":"746","article-title":"Pertussis and influenza vaccination among insured pregnant women\u2014Wisconsin, 2013\u20132014","volume":"64","author":"Koepke","year":"2015","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.11.056_b0290","series-title":"GAO Report","first-page":"12","article-title":"Medicare: many factors including administrative challenges, affect access to part D vaccinations","author":"U.S. Government Accountability Office","year":"2011"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0295","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/ajg.2012.380","article-title":"Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies","volume":"108","author":"Sharaf","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0300","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.2015","article-title":"Health benefits and cost-effectiveness of asymptomatic screening for hypertension and high cholesterol and aspirin counseling for primary prevention","volume":"15","author":"Dehmer","year":"2017","journal-title":"Ann Fam Med"},{"issue":"12","key":"10.1016\/j.vaccine.2018.11.056_b0305","first-page":"16","article-title":"Total cost-effectiveness of mammography screening strategies","volume":"26","author":"Mittmann","year":"2015","journal-title":"Health Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.056_b0310","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.11.056_b0315","unstructured":"A.J. Leidner, Overview of two economic models that assess the cost-effectiveness of herpes zoster vaccinations. Presented at the Advisory Committee on Immunization Practices June 2017 meeting. Atlanta (GA)."},{"issue":"16","key":"10.1016\/j.vaccine.2018.11.056_b0320","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0264-410X(03)00070-7","article-title":"The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines","volume":"21","author":"Nichol","year":"2003","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2018.11.056_b0325","doi-asserted-by":"crossref","first-page":"e22308","DOI":"10.1371\/journal.pone.0022308","article-title":"Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States","volume":"6","author":"Prosser","year":"2011","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.vaccine.2018.11.056_b0330","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-121-12-199412150-00008","article-title":"Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization","volume":"121","author":"Mullooly","year":"1994","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.vaccine.2018.11.056_b0335","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1056\/NEJM199409223311206","article-title":"The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community","volume":"331","author":"Nichol","year":"1994","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.056_b0340","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00043764-199705000-00006","article-title":"Cost-effectiveness of the influenza vaccine in a healthy, working-age population","volume":"39","author":"Campbell","year":"1997","journal-title":"J Occup Environ Med"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.11.056_b0345","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0264-410X(99)00110-3","article-title":"Clinical effectiveness and cost effectiveness of influenza vaccination among healthy working adults","volume":"17","author":"Nichol","year":"1999","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2018.11.056_b0350","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/jama.284.13.1655","article-title":"Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial","volume":"284","author":"Bridges","year":"2000","journal-title":"J Am Med Assoc"},{"issue":"12","key":"10.1016\/j.vaccine.2018.11.056_b0355","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1097\/00005650-200112000-00003","article-title":"Influenza vaccination, hospitalizations, and costs among members of a Medicare managed care plan","volume":"39","author":"Davis","year":"2001","journal-title":"Med Care"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.056_b0360","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/archinte.161.5.749","article-title":"Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza","volume":"161","author":"Nichol","year":"2001","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.056_b0365","doi-asserted-by":"crossref","first-page":"225","DOI":"10.7326\/0003-4819-137-4-200208200-00005","article-title":"Economic analysis of influenza vaccination and antiviral treatment for healthy working adults","volume":"137","author":"Lee","year":"2002","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.11.056_b0370","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0264-410X(02)00124-X","article-title":"Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years","volume":"20","author":"Nichol","year":"2002","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0375","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.amjmed.2004.03.044","article-title":"Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis","volume":"118","author":"Rothberg","year":"2005","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0380","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.amepre.2006.03.008","article-title":"Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older","volume":"31","author":"Maciosek","year":"2006","journal-title":"Am J Prev Med"},{"issue":"6","key":"10.1016\/j.vaccine.2018.11.056_b0385","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.AOG.0000210225.45986.99","article-title":"Cost-effectiveness of universal influenza vaccination in a pregnant population","volume":"107","author":"Roberts","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.vaccine.2018.11.056_b0390","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1002\/cncr.22670","article-title":"Cost-effectiveness of influenza vaccination in working-age cancer patients","volume":"109","author":"Avritscher","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.056_b0395","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/00019053-200826020-00006","article-title":"Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness","volume":"26","author":"Prosser","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.vaccine.2018.11.056_b0400","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1086\/649013","article-title":"Economic value of seasonal and pandemic influenza vaccination during pregnancy","volume":"49","author":"Beigi","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"48","key":"10.1016\/j.vaccine.2018.11.056_b0405","doi-asserted-by":"crossref","first-page":"7620","DOI":"10.1016\/j.vaccine.2010.09.053","article-title":"Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds","volume":"28","author":"Smith","year":"2010","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2018.11.056_b0410","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.vaccine.2010.12.078","article-title":"From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination","volume":"29","author":"Lee","year":"2011","journal-title":"Vaccine"},{"issue":"6 Suppl 1","key":"10.1016\/j.vaccine.2018.11.056_b0415","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.ajog.2011.04.009","article-title":"Influence of timing of seasonal influenza vaccination on effectiveness and cost-effectiveness in pregnancy","volume":"204","author":"Myers","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.vaccine.2018.11.056_b0420","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF03404197","article-title":"An incremental economic evaluation of targeted and universal influenza vaccination in pregnant women","volume":"102","author":"Skedgel","year":"2011","journal-title":"Can J Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.056_b0425","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/AOG.0b013e318242af27","article-title":"Cost-benefit analysis of in-hospital influenza vaccination of postpartum women","volume":"119","author":"Ding","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.vaccine.2018.11.056_b0430","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.ajem.2011.07.007","article-title":"Cost-effectiveness of influenza vaccination of older adults in the ED setting","volume":"30","author":"Patterson","year":"2012","journal-title":"Am J Emerg Med"},{"issue":"12","key":"10.1016\/j.vaccine.2018.11.056_b0435","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1473-3099(15)00249-2","article-title":"Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial","volume":"15","author":"Chit","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"27","key":"10.1016\/j.vaccine.2018.11.056_b0440","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1016\/j.vaccine.2016.04.057","article-title":"Cost-effectiveness of seasonal inactivated influenza vaccination among pregnant women","volume":"34","author":"Xu","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0445","doi-asserted-by":"crossref","first-page":"79","DOI":"10.7326\/0003-4819-104-1-79","article-title":"Cost effectiveness of vaccination against pneumococcal pneumonia: an update","volume":"104","author":"Sisk","year":"1986","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0450","first-page":"79","article-title":"Cost-effectiveness of pneumococcal vaccine: implications for managed care","volume":"5","author":"Holzer","year":"1993","journal-title":"J Res Pharm Econ"},{"issue":"16","key":"10.1016\/j.vaccine.2018.11.056_b0455","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.1997.03550160053038","article-title":"Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people","volume":"278","author":"Sisk","year":"1997","journal-title":"J Am Med Assoc"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.056_b0460","article-title":"Pneumococcal penicillin resistance and the cost-effectiveness of pneumococcal vaccine","volume":"15","author":"Herman","year":"1998","journal-title":"Infect Med"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.056_b0465","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0196-0644(99)70366-5","article-title":"An emergency department\u2013based pneumococcal vaccination program could save money and lives","volume":"33","author":"Stack","year":"1999","journal-title":"Ann Emerg Med"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.056_b0470","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF03404802","article-title":"A cost-effectiveness analysis of pneumococcal vaccination in street-involved, HIV-infected patients","volume":"91","author":"Marra","year":"2000","journal-title":"Can J Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0475","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1086\/313601","article-title":"Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps","volume":"30","author":"Pepper","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0480","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0749-3797(01)00312-9","article-title":"Cost utility of public clinics to increase pneumococcal vaccines in the elderly","volume":"21","author":"Mukamel","year":"2001","journal-title":"Am J Prev Med"},{"issue":"5 Suppl","key":"10.1016\/j.vaccine.2018.11.056_b0485","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1177\/027298902237705","article-title":"Cost-effectiveness of the pneumococcal vaccine in healthy younger adults","volume":"22","author":"Pepper","year":"2002","journal-title":"Med Decis Making"},{"issue":"12","key":"10.1016\/j.vaccine.2018.11.056_b0490","doi-asserted-by":"crossref","first-page":"960","DOI":"10.7326\/0003-4819-138-12-200306170-00007","article-title":"Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race","volume":"138","author":"Sisk","year":"2003","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.vaccine.2018.11.056_b0495","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.vaccine.2008.01.007","article-title":"Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis","volume":"26","author":"Smith","year":"2008","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2018.11.056_b0500","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1016\/j.vaccine.2009.03.059","article-title":"Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: a cost-effectiveness analysis","volume":"27","author":"Smith","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.056_b0505","first-page":"200","article-title":"Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic","volume":"16","author":"Smith","year":"2010","journal-title":"Am J Managed Care"},{"issue":"8","key":"10.1016\/j.vaccine.2018.11.056_b0510","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2012.169","article-title":"Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine","volume":"307","author":"Smith","year":"2012","journal-title":"J Am Med Assoc"},{"issue":"50","key":"10.1016\/j.vaccine.2018.11.056_b0515","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1016\/j.vaccine.2013.10.024","article-title":"Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions","volume":"31","author":"Cho","year":"2013","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2018.11.056_b0520","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1016\/j.vaccine.2013.06.037","article-title":"Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults","volume":"31","author":"Smith","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.056_b0525","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amepre.2012.11.035","article-title":"Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults","volume":"44","author":"Smith","year":"2013","journal-title":"Am J Prev Med"},{"issue":"11","key":"10.1016\/j.vaccine.2018.11.056_b0530","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"29","key":"10.1016\/j.vaccine.2018.11.056_b0535","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0540","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2018.11.056_b0545","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","article-title":"Health and economic implications of HPV vaccination in the United States","volume":"359","author":"Kim","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.056_b0550","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1524-4733.2009.00512.x","article-title":"Age-based programs for vaccination against HPV","volume":"12","author":"Elbasha","year":"2009","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.vaccine.2018.11.056_b0555","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1473-3099(10)70219-X","article-title":"Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis","volume":"10","author":"Kim","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.056_b0560","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.vaccine.2011.10.067","article-title":"Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada","volume":"30","author":"Tully","year":"2012","journal-title":"Vaccine"},{"issue":"51","key":"10.1016\/j.vaccine.2018.11.056_b0565","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1016\/j.vaccine.2014.10.052","article-title":"Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia","volume":"32","author":"Deshmukh","year":"2014","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2018.11.056_b0570","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJM198209093071103","article-title":"Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis","volume":"307","author":"Mulley","year":"1982","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.056_b0575","doi-asserted-by":"crossref","first-page":"298","DOI":"10.7326\/0003-4819-118-4-199302150-00009","article-title":"A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis","volume":"118","author":"Bloom","year":"1993","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0580","first-page":"97","article-title":"A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients","volume":"28","author":"Oddone","year":"1993","journal-title":"Health Serv Res"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2018.11.056_b0585","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0264-410X(02)00457-7","article-title":"Cost-effectiveness of hepatitis B vaccination of prison inmates","volume":"21","author":"Pisu","year":"2002","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2018.11.056_b0590","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.amepre.2006.01.017","article-title":"Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites","volume":"30","author":"Kim","year":"2006","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0595","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.amepre.2008.03.028","article-title":"Economic evaluation of delivering hepatitis B vaccine to injection drug users","volume":"35","author":"Hu","year":"2008","journal-title":"Am J Prev Med"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.056_b0600","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/003335490812300412","article-title":"Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the US","volume":"123","author":"Miriti","year":"2008","journal-title":"Public Health Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2018.11.056_b0605","doi-asserted-by":"crossref","first-page":"e78548","DOI":"10.1371\/journal.pone.0078548","article-title":"Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis","volume":"8","author":"Rossi","year":"2013","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.vaccine.2018.11.056_b0610","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF02599616","article-title":"Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysis","volume":"8","author":"Balestra","year":"1993","journal-title":"J Gen Intern Med"},{"issue":"7","key":"10.1016\/j.vaccine.2018.11.056_b0615","doi-asserted-by":"crossref","first-page":"e6284","DOI":"10.1371\/journal.pone.0006284","article-title":"Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects","volume":"4","author":"Coudeville","year":"2009","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.056_b0620","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1542\/peds.2010-0796","article-title":"Use of models to identify cost-effective interventions: pertussis vaccination for pediatric health care workers","volume":"128","author":"Greer","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.056_b0625","doi-asserted-by":"crossref","first-page":"e72723","DOI":"10.1371\/journal.pone.0072723","article-title":"Cost-effectiveness of Tdap vaccination of adults aged >=65 years in the prevention of pertussis in the US: a dynamic model of disease transmission","volume":"9","author":"McGarry","year":"2014","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.vaccine.2018.11.056_b0630","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/aje\/kwv347","article-title":"Cost-effectiveness of pertussis vaccination during pregnancy in the United States","volume":"183","author":"Atkins","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"15","key":"10.1016\/j.vaccine.2018.11.056_b0635","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.vaccine.2016.02.027","article-title":"Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States","volume":"34","author":"Kamiya","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.056_b0640","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-145-5-200609050-00004","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"145","author":"Hornberger","year":"2006","journal-title":"Ann Intern Med"},{"issue":"49","key":"10.1016\/j.vaccine.2018.11.056_b0645","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","article-title":"Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"25","author":"Pellissier","year":"2007","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2018.11.056_b0650","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1086\/514342","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"44","author":"Rothberg","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.056_b0655","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4161\/hv.4.3.5686","article-title":"The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia","volume":"4","author":"Brisson","year":"2008","journal-title":"Human Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2018.11.056_b0660","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2165\/11314010-000000000-00000","article-title":"Cost effectiveness of herpes zoster vaccine in Canada","volume":"27","author":"Najafzadeh","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.056_b0665","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11606-016-3844-6","article-title":"Determining the optimal vaccination schedule for herpes zoster: a cost-effectiveness analysis","volume":"32","author":"Le","year":"2016","journal-title":"J Gen Intern Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18315810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18315810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:29:21Z","timestamp":1759400961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18315810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":133,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0264410X18315810"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.056","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of adult vaccinations: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}